Cap Innov'Est 2

Manufacturer of medical devices for the treatment of non-contact wounds. The company engages in developing medical devices for the treatment of wounds, without contact and in a controlled atmosphere, built around three therapeutic axes, the isolation of a nosocomial risk, visual monitoring of the evolution and personalized care of the type and stage of the wound, as well as a daily adjustment of the medical protocol, thereby improving the lives of patients suffering from complex wounds that are difficult to treat with standard therapies.

Opencell, founded in 2015, specializes in providing an open-source monetization and billing platform designed to address the complexities of subscription and usage-based billing. Building on a telco billing project initiated in 2007, Opencell aims to bridge the gap between expensive legacy billing systems and overly simplistic software solutions. The platform is tailored for diverse sectors, including telecommunications, cloud services, IoT, and utilities, enabling businesses to efficiently manage their revenue streams. With over 40 successful implementations across various industries and countries, Opencell offers a comprehensive solution that simplifies revenue management, making complex billing processes accessible to a wide range of clients.

Defymed SAS is a French company that specializes in developing implantable bio-artificial medical devices for therapeutic applications, particularly in the field of diabetes management. The company’s flagship product, MAILPAN, is a bio-artificial pancreas designed to treat diabetes by utilizing insulin-secreting cells that respond to the patient's physiological needs. Additionally, Defymed offers ExOlin, an insulin delivery device aimed at facilitating insulin administration for individuals with diabetes. Beyond diabetes, Defymed's bio-artificial devices also have potential applications in cell therapies for various liver and kidney diseases, including acute liver failure and chronic hepatitis conditions. Founded in 1996 and based in Strasbourg, France, Defymed originated as a spin-off from the European Center for Diabetes Studies, focusing on innovative solutions to improve patient treatment outcomes and comfort.

Syndivia SAS develops antibody-drug conjugates (ADC) for cancer treatment. The company provides therapeutic modalities for solid cancers based on specific targeting of the tumor microenvironment and anatomical hallmarks. It offers lead programs such as SDV1001 for pancreatic cancer and colorectal cancer and SDV1101 for breast cancer and liposarcoma. Syndivia SAS was incorporated in 2014 and is based in Illkirch-Graffenstaden, France.

Urania Therapeutics is a biopharmaceutical company focused on developing innovative therapies for genetic diseases and cancers caused by mutations. The company specializes in the identification and creation of readthrough compounds that address premature stop codons during protein synthesis. By facilitating the production of full-length proteins, these compounds aim to treat a variety of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its unique structure-based drug design platform, Urania Therapeutics seeks to restore the production of functional proteins, thereby offering new therapeutic options for patients with these challenging conditions.

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies. Exeliom develops a new class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system. The company was founded in 2016 and is headquartered in Dijon, France.

Medsenic SAS is a privately held pharmaceutical company based in Paris, France, founded in 2010. The company specializes in the development and manufacturing of drugs aimed at treating autoimmune diseases, including systemic lupus erythematosus and graft-versus-host disease. Medsenic is known for its arsenic trioxide product, which is utilized in the treatment of acute promyelocytic leukemia, demonstrating significant effectiveness in achieving remissions and addressing severe medical conditions.

Opencell, founded in 2015, specializes in providing an open-source monetization and billing platform designed to address the complexities of subscription and usage-based billing. Building on a telco billing project initiated in 2007, Opencell aims to bridge the gap between expensive legacy billing systems and overly simplistic software solutions. The platform is tailored for diverse sectors, including telecommunications, cloud services, IoT, and utilities, enabling businesses to efficiently manage their revenue streams. With over 40 successful implementations across various industries and countries, Opencell offers a comprehensive solution that simplifies revenue management, making complex billing processes accessible to a wide range of clients.

Inoviem Scientific SAS is a contract research biotechnology company based in Strasbourg, France, specializing in preclinical and clinical services aimed at accelerating drug development. Founded in 2011, the company employs advanced proprietary technologies to analyze drug-target interactions in physiological conditions and human tissues. Its key technologies include physiological intermolecular modulation spectroscopy, which examines the interactions of exogenous molecules with tissues, and the nematic protein organization technique, which isolates protein complexes linked to these molecules. Inoviem also utilizes multiplex cross sandwich immunoassays for detailed reconstruction of protein complexes. The company serves a diverse clientele, including private and academic laboratories, as well as pharmaceutical and biotechnology industries, providing services such as target identification, lead optimization, biomarker development, and clinical development. By leveraging its innovative technologies, Inoviem Scientific aims to enhance the accuracy of drug development processes, reduce attrition rates, and ultimately facilitate the introduction of new therapeutic compounds to the market.

PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides. Our innovative approach enables the identification of peptidomimetic candidates interfering with the hetero- and/or the homodimerization of target receptors. PeptiMimesis will develop its pipeline against key targets in the fields of oncology, immuno-oncology and immune disease and is open to initiate collaboration with pharma partners on receptors of interest.

FiberMetrix SAS, founded in 2014 and based in Entzheim, France, specializes in the manufacture of detectors for real-time monitoring of radiation doses in medical and industrial sectors. The company offers innovative solutions such as the IVIscan dose measurement system and the IVIyou software interface, which can be accessed from any computer connected to the internal network. Utilizing patented optical fiber technology, FiberMetrix develops both fully integrated and handheld sensors that provide automatic feedback on radiation exposure, enhancing awareness for both patients and occupational users. Their products are designed to facilitate rapid and accurate radiation dose measurement, catering to various applications within radiation-based domains.

Wizzvet is the first interactive platform for veterinary telemedicine in the form of a professional social network. WIZZVET offers a huge and up-to-date range of web conferences with two to three new online courses each week granting you continuing education points.

PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides. Our innovative approach enables the identification of peptidomimetic candidates interfering with the hetero- and/or the homodimerization of target receptors. PeptiMimesis will develop its pipeline against key targets in the fields of oncology, immuno-oncology and immune disease and is open to initiate collaboration with pharma partners on receptors of interest.

Opencell, founded in 2015, specializes in providing an open-source monetization and billing platform designed to address the complexities of subscription and usage-based billing. Building on a telco billing project initiated in 2007, Opencell aims to bridge the gap between expensive legacy billing systems and overly simplistic software solutions. The platform is tailored for diverse sectors, including telecommunications, cloud services, IoT, and utilities, enabling businesses to efficiently manage their revenue streams. With over 40 successful implementations across various industries and countries, Opencell offers a comprehensive solution that simplifies revenue management, making complex billing processes accessible to a wide range of clients.

Defymed SAS is a French company that specializes in developing implantable bio-artificial medical devices for therapeutic applications, particularly in the field of diabetes management. The company’s flagship product, MAILPAN, is a bio-artificial pancreas designed to treat diabetes by utilizing insulin-secreting cells that respond to the patient's physiological needs. Additionally, Defymed offers ExOlin, an insulin delivery device aimed at facilitating insulin administration for individuals with diabetes. Beyond diabetes, Defymed's bio-artificial devices also have potential applications in cell therapies for various liver and kidney diseases, including acute liver failure and chronic hepatitis conditions. Founded in 1996 and based in Strasbourg, France, Defymed originated as a spin-off from the European Center for Diabetes Studies, focusing on innovative solutions to improve patient treatment outcomes and comfort.

Inoviem Scientific SAS is a contract research biotechnology company based in Strasbourg, France, specializing in preclinical and clinical services aimed at accelerating drug development. Founded in 2011, the company employs advanced proprietary technologies to analyze drug-target interactions in physiological conditions and human tissues. Its key technologies include physiological intermolecular modulation spectroscopy, which examines the interactions of exogenous molecules with tissues, and the nematic protein organization technique, which isolates protein complexes linked to these molecules. Inoviem also utilizes multiplex cross sandwich immunoassays for detailed reconstruction of protein complexes. The company serves a diverse clientele, including private and academic laboratories, as well as pharmaceutical and biotechnology industries, providing services such as target identification, lead optimization, biomarker development, and clinical development. By leveraging its innovative technologies, Inoviem Scientific aims to enhance the accuracy of drug development processes, reduce attrition rates, and ultimately facilitate the introduction of new therapeutic compounds to the market.

Bionext S.A. is a biotechnology company based in Strasbourg, France, founded in 2009. It specializes in bioinformatics and the development of three-dimensional molecular visualization software tailored for the pharmaceuticals and biotechnology sectors. The company focuses on integrating big data, cloud computing, and OMICS data to enhance drug discovery processes. Bionext's platform enables visualization and simulation of drug interactions within human cells, facilitating a deeper understanding of drug behavior and aiding in drug repurposing and profile assessment. Additionally, the Bionext Virtual Screening platform models the cellular environment to support high-throughput screening, allowing for early assessment of molecular functions, side effects, and efficacy throughout the development stages of new compounds across various industries, including pharmacy, cosmetics, and agri-food.